Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Kava on Anxiety and Stress in Cancer Survivors
NCT06213298Phase 1Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anxiety disorder and stress comparing Kava with Placebo (2 arms). Primary endpoints: PROMIS anxiety measure score at 14 days and Adverse Events at 14 days. Planned start Jun 2024; status: withdrawn.
02
Drugs
kava
03
Conditions
anxiety disorderstress
Beyond the preview
Go deeper on NCT06213298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213298.